Cargando…
Respiratory muscle training with enzyme replacement therapy improves muscle strength in late - onset Pompe disease
BACKGROUND: Pompe disease is an autosomal recessive metabolic disorder caused by the deficiency of the lysosomal enzyme acid α-glucosidase. This deficiency leads to glycogen accumulation in the lysosomes of muscle tissue causing progressive muscular weakness particularly of the respiratory system. E...
Autores principales: | Mitja, Jevnikar, Metka, Kodric, Fabiana, Cantarutti, Cifaldi, Rossella, Longo, Cinzia, Rossana, Della Porta, Bruno, Bembi, Marco, Confalonieri |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471388/ https://www.ncbi.nlm.nih.gov/pubmed/28649546 http://dx.doi.org/10.1016/j.ymgmr.2015.09.007 |
Ejemplares similares
-
Clinical Characterization and Predictive Factors for Progression in a Cohort of Patients with Interstitial Lung Disease and Features of Autoimmunity: The Need for a Revision of IPAF Classification Criteria
por: Bozzao, Francesco, et al.
Publicado: (2023) -
Muscle Proteomic Profile before and after Enzyme Replacement Therapy in Late-Onset Pompe Disease
por: Moriggi, Manuela, et al.
Publicado: (2021) -
Practical Recommendations for Diagnosis and Management of Respiratory Muscle Weakness in Late-Onset Pompe Disease
por: Boentert, Matthias, et al.
Publicado: (2016) -
Pulmonary Sarcoidosis and Immune Dysregulation: A Pilot Study on Possible Correlation
por: Cifaldi, Rossella, et al.
Publicado: (2023) -
Nintedanib in Idiopathic Pulmonary Fibrosis: Tolerability and Safety in a Real Life Experience in a Single Centre in Patients also Treated with Oral Anticoagulant Therapy
por: Ruaro, Barbara, et al.
Publicado: (2023)